


## Atreleuton

Cat. No.:	HY-117853
CAS No.:	154355-76-7
Molecular Formula:	C <sub>16</sub> H <sub>15</sub> FN <sub>2</sub> O <sub>2</sub> S
Molecular Weight:	318.37
Target:	Lipoxygenase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation <sup>[1][2][3]</sup> . Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC <sub>50</sub> & Target	5-LO

### REFERENCES

- [1]. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc.
- [2]. Reid JJ, et al. ABT-761 (Abbott). *Curr Opin Investig Drugs*. 2001 Jan;2(1):68-71.
- [3]. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. *J Pharmacol Exp Ther*. 1997 Mar;280(3):1366-73.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA